S&P 500   3,276.24 (+1.01%)
DOW   28,722.85 (+0.66%)
QQQ   221.45 (+1.54%)
AAPL   317.69 (+2.83%)
FB   217.79 (+1.36%)
MSFT   165.46 (+1.96%)
GOOGL   1,450.50 (+1.31%)
AMZN   1,853.25 (+1.36%)
CGC   23.92 (+10.95%)
NVDA   247.97 (+3.23%)
BABA   210.23 (+2.32%)
MU   56.47 (+1.91%)
GE   11.73 (+2.53%)
TSLA   566.90 (+1.59%)
AMD   50.53 (+2.58%)
T   38.58 (+0.86%)
ACB   1.97 (+4.23%)
F   8.97 (+0.90%)
NFLX   348.52 (+1.64%)
PRI   120.64 (+1.31%)
BAC   33.24 (+1.19%)
DIS   138.37 (+1.82%)
GILD   64.36 (+0.83%)
S&P 500   3,276.24 (+1.01%)
DOW   28,722.85 (+0.66%)
QQQ   221.45 (+1.54%)
AAPL   317.69 (+2.83%)
FB   217.79 (+1.36%)
MSFT   165.46 (+1.96%)
GOOGL   1,450.50 (+1.31%)
AMZN   1,853.25 (+1.36%)
CGC   23.92 (+10.95%)
NVDA   247.97 (+3.23%)
BABA   210.23 (+2.32%)
MU   56.47 (+1.91%)
GE   11.73 (+2.53%)
TSLA   566.90 (+1.59%)
AMD   50.53 (+2.58%)
T   38.58 (+0.86%)
ACB   1.97 (+4.23%)
F   8.97 (+0.90%)
NFLX   348.52 (+1.64%)
PRI   120.64 (+1.31%)
BAC   33.24 (+1.19%)
DIS   138.37 (+1.82%)
GILD   64.36 (+0.83%)
S&P 500   3,276.24 (+1.01%)
DOW   28,722.85 (+0.66%)
QQQ   221.45 (+1.54%)
AAPL   317.69 (+2.83%)
FB   217.79 (+1.36%)
MSFT   165.46 (+1.96%)
GOOGL   1,450.50 (+1.31%)
AMZN   1,853.25 (+1.36%)
CGC   23.92 (+10.95%)
NVDA   247.97 (+3.23%)
BABA   210.23 (+2.32%)
MU   56.47 (+1.91%)
GE   11.73 (+2.53%)
TSLA   566.90 (+1.59%)
AMD   50.53 (+2.58%)
T   38.58 (+0.86%)
ACB   1.97 (+4.23%)
F   8.97 (+0.90%)
NFLX   348.52 (+1.64%)
PRI   120.64 (+1.31%)
BAC   33.24 (+1.19%)
DIS   138.37 (+1.82%)
GILD   64.36 (+0.83%)
S&P 500   3,276.24 (+1.01%)
DOW   28,722.85 (+0.66%)
QQQ   221.45 (+1.54%)
AAPL   317.69 (+2.83%)
FB   217.79 (+1.36%)
MSFT   165.46 (+1.96%)
GOOGL   1,450.50 (+1.31%)
AMZN   1,853.25 (+1.36%)
CGC   23.92 (+10.95%)
NVDA   247.97 (+3.23%)
BABA   210.23 (+2.32%)
MU   56.47 (+1.91%)
GE   11.73 (+2.53%)
TSLA   566.90 (+1.59%)
AMD   50.53 (+2.58%)
T   38.58 (+0.86%)
ACB   1.97 (+4.23%)
F   8.97 (+0.90%)
NFLX   348.52 (+1.64%)
PRI   120.64 (+1.31%)
BAC   33.24 (+1.19%)
DIS   138.37 (+1.82%)
GILD   64.36 (+0.83%)
Log in

NASDAQ:AUPH - Aurinia Pharmaceuticals Stock Price, Forecast & News

$18.56
+0.19 (+1.03 %)
(As of 01/28/2020 04:00 PM ET)
Today's Range
$17.81
Now: $18.56
$18.70
50-Day Range
$17.67
MA: $19.84
$21.49
52-Week Range
$3.52
Now: $18.56
$21.93
Volume1.37 million shs
Average Volume1.95 million shs
Market Capitalization$2.07 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.68
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AUPH
CUSIPN/A
Phone250-744-2487

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$460,000.00
Book Value$1.32 per share

Profitability

Net Income$-64,120,000.00
Net Margins-19,483.96%

Miscellaneous

Employees39
Market Cap$2.07 billion
Next Earnings Date3/17/2020 (Estimated)
OptionableOptionable

Receive AUPH News and Ratings via Email

Sign-up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter.


Aurinia Pharmaceuticals (NASDAQ:AUPH) Frequently Asked Questions

What is Aurinia Pharmaceuticals' stock symbol?

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) issued its earnings results on Thursday, November, 14th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.02. The biotechnology company had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.05 million. Aurinia Pharmaceuticals had a negative return on equity of 50.79% and a negative net margin of 19,483.96%. View Aurinia Pharmaceuticals' Earnings History.

When is Aurinia Pharmaceuticals' next earnings date?

Aurinia Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 17th 2020. View Earnings Estimates for Aurinia Pharmaceuticals.

What price target have analysts set for AUPH?

8 analysts have issued 1 year price targets for Aurinia Pharmaceuticals' stock. Their forecasts range from $11.00 to $32.00. On average, they anticipate Aurinia Pharmaceuticals' stock price to reach $22.29 in the next year. This suggests a possible upside of 20.1% from the stock's current price. View Analyst Price Targets for Aurinia Pharmaceuticals.

What is the consensus analysts' recommendation for Aurinia Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aurinia Pharmaceuticals.

Has Aurinia Pharmaceuticals been receiving favorable news coverage?

News stories about AUPH stock have been trending very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aurinia Pharmaceuticals earned a news impact score of -3.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Aurinia Pharmaceuticals.

Are investors shorting Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals saw a decline in short interest in the month of January. As of January 15th, there was short interest totalling 5,500,000 shares, a decline of 23.7% from the December 31st total of 7,210,000 shares. Based on an average trading volume of 3,460,000 shares, the short-interest ratio is presently 1.6 days. Currently, 6.9% of the company's shares are sold short. View Aurinia Pharmaceuticals' Current Options Chain.

Who are some of Aurinia Pharmaceuticals' key competitors?

What other stocks do shareholders of Aurinia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Array Biopharma (ARRY), Cara Therapeutics (CARA), Micron Technology (MU), Exelixis (EXEL), Corbus Pharmaceuticals (CRBP), Novavax (NVAX) and Synergy Pharmaceuticals (SGYP).

Who are Aurinia Pharmaceuticals' key executives?

Aurinia Pharmaceuticals' management team includes the folowing people:
  • Mr. Michael R. Martin, Co-Founder & COO
  • Mr. Dennis Bourgeault CPA, C.A., CFO & Sec.
  • Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.
  • Dr. Richard M. Glickman, Advisor (Age 61)
  • Dr. Neil Solomons M.D., Chief Medical Officer

Who are Aurinia Pharmaceuticals' major shareholders?

Aurinia Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include SG Americas Securities LLC (0.00%), Patriot Financial Group Insurance Agency LLC (0.00%), Lindbrook Capital LLC (0.00%) and Steward Partners Investment Advisory LLC (0.00%).

Which institutional investors are selling Aurinia Pharmaceuticals stock?

AUPH stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC and Patriot Financial Group Insurance Agency LLC.

Which institutional investors are buying Aurinia Pharmaceuticals stock?

AUPH stock was bought by a variety of institutional investors in the last quarter, including Lindbrook Capital LLC and Steward Partners Investment Advisory LLC.

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aurinia Pharmaceuticals' stock price today?

One share of AUPH stock can currently be purchased for approximately $18.56.

How big of a company is Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals has a market capitalization of $2.07 billion and generates $460,000.00 in revenue each year. The biotechnology company earns $-64,120,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. Aurinia Pharmaceuticals employs 39 workers across the globe.View Additional Information About Aurinia Pharmaceuticals.

What is Aurinia Pharmaceuticals' official website?

The official website for Aurinia Pharmaceuticals is http://www.auriniapharma.com/.

How can I contact Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals' mailing address is 1203-4464 MARKHAM STREET, VICTORIA A1, V8Z 7X8. The biotechnology company can be reached via phone at 250-744-2487 or via email at [email protected]


MarketBeat Community Rating for Aurinia Pharmaceuticals (NASDAQ AUPH)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  474 (Vote Outperform)
Underperform Votes:  300 (Vote Underperform)
Total Votes:  774
MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote "Outperform" if you believe AUPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/28/2020 by MarketBeat.com Staff

Featured Article: What is a recession?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel